SAN DIEGO, CA--(Marketwired - Apr 4, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (
"2015 marks our second year of revenue generation and along with the beginning of 2016 has been a transformative time for Innovus Pharma as we continued our acquisition streak to bring in more revenues and products along with the expansion of our commercial partnerships," said Dr. Damaj President & CEO of the Company.
Below are the additional accomplishments of the Company during 2015 and the beginning of 2016:
- Grew Pipeline to 13 Commercialized Products and 3 Pipeline Products:
- Commercial: Zestra®, EjectDelay® , Sensum+®,Zestra Glide®, Vesele®, Androferti®, BTH® Testosterone, BTH® HGA, BTH® Vision, BTH® Blood Sugar, BTH® GCBE, BTH® Colon Cleans, BTH® Ketones.
- Pipeline: (Fluticare™ OTC (Fluticasone propionate NS), Androvit® and Urocis® XR
- Launched Androferti® in the US
- Filed Androferti® with Health Canada though our partner Orimed Pharma
- Acquisition of Beyond Human Franchise
- Product sold over $1.3 M in 2014 and over $2.2 M in 2015.
- Completed acquisition in March 2016
- Signed Eight Commercial Partnerships
- Eight commercial partnerships signed with over $5000M in potential sales milestones plus royalties in 60 countries
- Strengthened our Financials
- Repaid all outstanding and due debt
- Raised close to $2.5M
"With all the progress and growth the Company is doing, we've initiated our plan for a potential uplisting to the NYSE-MKT exchange market with a goal of uplisting in 2016," continued Dr. Damaj
The Company will have a shareholder update call on:
When: Wednesday, April 6, 2016 4:05 EDT/1:05 PDT
Length: ~ 15 minute presentation followed by a 20 minute Question and Answer session
Dial in number: 530-881-1212
Meeting ID: 615-253-385#
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products.. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company
Contact Information:
Contact:
Reuven Rubinson
Vice President of Finance
rreubinson@innovuspharma.com
858.964-5123